Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients

Current Opinion in Infectious Diseases

Volumn 24, Issue 6, 2011, Pages 545-553

  Bow, Eric James ^a  

^a Clinical and Academic Services   (Canada)

Author keywords

Aerobic Gram negative bacilli; Antibacterial prophylaxis; Clostridium difficile; Fluoroquinolones; Methicillin resistant staphylococcus aureus; Multiclass antimicrobial resistance; Vancomycin resistant enterococci

Indexed keywords

AMOXICILLIN; AMPICILLIN; CARBAPENEM; CARBAPENEM DERIVATIVE; CEPHALOSPORIN; CIPROFLOXACIN; CLAVULANIC ACID; CLOXACILLIN; GATIFLOXACIN; LEVOFLOXACIN; LINCOSAMIDE; PENICILLIN G; PLACEBO; QUINOLONE DERIVATIVE; STREPTOMYCIN; SULFAMETHOXAZOLE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TRIMETHOPRIM; VANCOMYCIN;

AEROBIC CAPACITY; ANTIBIOTIC RESISTANCE; CANCER PATIENT; CLOSTRIDIUM DIFFICILE; DIARRHEA; FEBRILE NEUTROPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEUTROPHIL COUNT; PRACTICE GUIDELINE; REMISSION; REVIEW; STAPHYLOCOCCUS AUREUS; UROSEPSIS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; NEUTROPENIA; PREVALENCE;

EID: 80055020913     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834cf054     Document Type: Review

References (94)

1. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142:979-995. (Pubitemid 40840313)
2. Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006; 107:1743-1751. (Pubitemid 44582942)
3. Vidal L, Paul M, Ben-Dor I, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 2004:CD003992.
4. Bliziotis IA, Michalopoulos A, Kasiakou SK, et al. Ciprofloxacin vs. an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: A meta-analysis of randomized controlled trials. Mayo Clin Proc 2005; 80:1146-1156. (Pubitemid 41235474)
5. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (SUPPL. 2):S27-S72. (Pubitemid 46290553)
6. Rotschafer JC, Ullman MA, Sullivan CJ. Optimal use of fluoroquinolones in the intensive care unit setting. Crit Care Clin 2011; 27:95-106.
7. Cohn SM, Lipsett PA, Buchman TG, et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000; 232:254-262. (Pubitemid 30616727)
8. Solomkin JS, Wilson SE, Christou NV, et al. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections. Ann Surg 2001; 233:79-87. (Pubitemid 32043607)
9. Linder JA, Huang ES, Steinman MA, et al. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005; 118:259-268. (Pubitemid 40312637)
10. Johnson L, Sabel A, Burman WJ, et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 2008; 121:876-884.
11. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: A systematic review and meta-analysis. J Antimicrob Chemother 2007; 60:913-920. (Pubitemid 47617735)
12. Cullen M, Baijal S. Prevention of febrile neutropenia: use of prophylactic antibiotics. Br J Cancer 2009; 101 (SUPPL. 1):S11-S14.
13. Bow EJ. Prophylaxis. In: Kleinberg M, editor. Managing infections in patients with hematological malignancies. Humana Press; 2009. pp. 259-308.
14. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24:111-118. (Pubitemid 40487379)
15. Ng ES, Liew Y, Earnest A, et al. Audit of fluoroquinolone prophylaxis against chemotherapy-induced febrile neutropenia in a hospital with highly prevalent fluoroquinolone resistance. Leuk Lymphoma 2011; 52:131-133.
16. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038-3051. (Pubitemid 30644129)
17. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56-e93.
18. Rangaraj G, Granwehr BP, Jiang Y, et al. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 2010; 116:967-973.
19. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56:52-59. (Pubitemid 41418336)
20. Rodriguez-Bano J, Navarro MD, Romero L, et al. Bacteremia due to extendedspectrum beta -lactamase-producing Escherichia coli in the CTX-M era: A new clinical challenge. Clin Infect Dis 2006; 43:1407-1414. (Pubitemid 44845640)
21. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61:273-281.
22. Valverde A, Coque TM, Sanchez-Moreno MP, et al. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42:4769-4775. (Pubitemid 39362401)
23. Rodriguez-Bano J, Alcala JC, Cisneros JM, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168:1897-1902.
24. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8:159-166. (Pubitemid 351249250)
25. Falagas ME, Karageorgopoulos DE. Extended-spectrum beta- lactamaseproducing organisms. J Hosp Infect 2009; 73:345-354.
26. Bush K, Macalintal C, Rasmussen BA, et al. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother 1993; 37:851-858. (Pubitemid 23096890)
27. Rozenberg-Arska M, Dekker AW, Verhoef J. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. J Infect Dis 1985; 152:104-107. (Pubitemid 15038841)
28. Bow E, Rayner E, Scott BA, Louie TJ. Selective gut decontamination with nalidixic acid or trimethoprim-sulfamethoxazole for infection prophylaxis in neutropenic cancer patients: relationship of efficacy to antimicrobial spectrum and timing of administration. Antimicrob Agents Chemother 1987; 31:551-557. (Pubitemid 17054336)
29. Carratala J, Fernandez-Sevilla A, Tubau F, et al. Emergence of fluoroquinolone- resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996; 40:503-505. (Pubitemid 26049371)
30. Gomez L, Garau J, Estrada C, et al. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer 2003; 97:419-424. (Pubitemid 36133809)
31. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl JMed 1994; 330:1240-1241. (Pubitemid 24122001)
32. Kern WV, Andriof E, Oethinger M, et al. Emergence of fluoroquinoloneresistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994; 38:681-687. (Pubitemid 24114001)
33. Baum HV, Franz U, Geiss HK. Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection 2000; 28:278-281.
34. Razonable RR, Litzow MR, Khaliq Y, et al. Bacteremia due to viridans group Streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 2002; 34:1469-1474. (Pubitemid 34553706)
35. Reuter S, Kern WV, Sigge A, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005; 40:1087-1093. (Pubitemid 40490230)
36. Saito T, Yoshioka S, Iinuma Y, et al. Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology-oncology unit. Eur J Clin Microbiol Infect Dis 2008; 27:209-216.
37. Chong Y, Yakushiji H, Ito Y, Kamimura T. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis 2011; 15:e277-e281.
38. Cattaneo C, Quaresmini G, Casari S, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008; 61:721-728. (Pubitemid 351321152)
39. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007; 59:5-22. (Pubitemid 46017895)
40. Lingaratnam S, Thursky KA, Slavin MA. Fluoroquinolone prophylaxis: A word of caution. Leuk Lymphoma 2011; 52:5-6.
41. Ng ES, Liew Y, Koh LP, Hsu LY. Fluoroquinolone prophylaxis against febrile neutropenia in areas with high fluoroquinolone resistance: an Asian perspective. J Formos Med Assoc 2010; 109:624-631.
42. Hsu LY, Tan TY, Jureen R, et al. Antimicrobial drug resistance in Singapore hospitals. Emerg Infect Dis 2007; 13:1944-1947. (Pubitemid 350252975)
43. Ko WC, Hsueh PR. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intraabdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006. J Infect 2009; 59:95-103.
44. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet 2005; 365:579-587. (Pubitemid 40247914)
45. Walsh TR, Toleman MA., The new medical challenge: Why NDM-1? Why Indian? Expert Rev Anti Infect Ther 2011; 9:137-141
46. Phillips I, Culebras E, Moreno F, Baquero F. Induction of the SOS response by new 4-quinolones. J Antimicrob Chemother 1987; 20:631-638. (Pubitemid 18036576)
47. Beaber JW, Hochhut B, Waldor MK. SOS response promotes horizontal dissemination of antibiotic resistance genes. Nature 2004; 427:72-74. (Pubitemid 38094823)
48. Diwan V, Tamhankar AJ, Khandal RK, et al. Antibiotics and antibiotic-resistant bacteria in waters associated with a hospital in Ujjain, India. BMC Public Health 2010; 10:414.
49. Mendell TH. Staphylococcal septicemia: A review of thirty-five cases, with six recoveries, twenty-nine deaths, and sixteen autopsies. Arch Intern Med 1939; 63:1068-1083.
50. Spink WW, Hansen AE, Paine JR. Staphylococcal bacteremia, treatment with sulfapyridine and sulfathiazole. Arch Intern Med 1941; 67:25-35.
51. Spink WW. Staphylococcal infections and the problem of antibiotic-resistant Staphylococci. Arch Intern Med 1954; 94:167-196.
52. Dancer SJ. The effect of antibiotics on methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2008; 61:246-253.
53. Jevons MP, Coe AW, Parker MT. Methicillin resistance in staphylococci. Lancet 1963; 1:904-907.
54. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003; 36:53-59. (Pubitemid 36099097)
55. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988; 109:619-624.
56. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227-1231. (Pubitemid 20177385)
57. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674-680.
58. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155. (Pubitemid 30485502)
59. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36:429-439. (Pubitemid 36241308)
60. Berntsen CA, McDermott W. Increased transmissibility of staphylococci to patients receiving an antimicrobial drug. N Engl J Med 1960; 262:637-642.
61. Hastings PJ, Rosenberg SM, Slack A. Antibiotic-induced lateral transfer of antibiotic resistance. Trends Microbiol 2004; 12:401-404. (Pubitemid 39178589)
62. Maiques E, Ubeda C, Campoy S, et al. Beta-lactam antibiotics induce the SOS response and horizontal transfer of virulence factors in Staphylococcus aureus. J Bacteriol 2006; 188:2726-2729.
63. Goerke C, Koller J, Wolz C. Ciprofloxacin and trimethoprim cause phage induction and virulence modulation in Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50:171-177. (Pubitemid 43042918)
64. Weber SG, Gold HS, Hooper DC, et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9:1415-1422. (Pubitemid 37356215)
65. Charbonneau P, Parienti JJ, Thibon P, et al. Fluoroquinolone use and methicillin- resistant Staphylococcus aureus isolation rates in hospitalized patients: A quasi experimental study. Clin Infect Dis 2006; 42:778-784. (Pubitemid 43363932)
66. Quilty S, Kwok G, Hajkowicz K, Currie B. High incidence of methicillinresistant Staphylococcus aureus sepsis and death in patients with febrile neutropenia at Royal Darwin Hospital. Intern Med J 2009; 39:557-559.
67. Schramm GE, Johnson JA, Doherty JA, et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 2006; 34:2069-2074. (Pubitemid 44305607)
68. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136:1237-1248.
69. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-1260. (Pubitemid 41532667)
70. Louie TJ, Meddings J. Clostridium difficile infection in hospitals: risk factors and responses. CMAJ 2004; 171:45-46. (Pubitemid 38925118)
71. Beaulieu M, Thirion DJ, Williamson D, Pichette G. Clostridium difficile-associated diarrhea outbreaks: the name of the game is isolation and cleaning. Clin Infect Dis 2006; 42:725; author reply 727-729. (Pubitemid 43271390)
72. Weiss K. Poor infection control, not fluoroquinolones, likely to be primary cause of Clostridium difficile-associated diarrhea outbreaks in Quebec. Clin Infect Dis 2006; 42:725-727; author reply 727-729. (Pubitemid 43271391)
73. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1:101-114. (Pubitemid 33586045)
74. Spencer RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother 1998; 41 (SUPPL. C): 21-27. (Pubitemid 28230296)
75. Bow EJ, Mandell LA, Louie TJ, et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented Gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med 1996; 125:183-190. (Pubitemid 126449260)
76. Schimpff SC, Young VM, Greene WH, et al. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med 1972; 77:707-714.
77. van de Leur JJ, Vollaard EJ, Janssen AJ, Dofferhoff AS. Influence of low dose ciprofloxacin on microbial colonization of the digestive tract in healthy volunteers during normal and during impaired colonization resistance. Scand J Infect Dis 1997; 29:297-300.
78. Edlund C, Sjostedt S, Nord CE. Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora. Scand J Infect Dis 1997; 29:383-386.
79. Edlund C, Nord CE. Ecological effect of gatifloxacin on the normal human intestinal microflora. J Chemother 1999; 11:50-53. (Pubitemid 29095602)
80. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004; 38:640-645. (Pubitemid 38333858)
81. Gerding DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 2004; 38:646-648. (Pubitemid 38333859)
82. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171:33-38. (Pubitemid 38925116)
83. Edmond MB, Ober JF, Dawson JD, et al. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996; 23:1234-1239. (Pubitemid 26423158)
84. Landry SL, Kaiser DL, Wenzel RP. Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: A controlled study. Am J Infect Control 1989; 17:323-329. (Pubitemid 20068451)
85. Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995; 20:1126-1133.
86. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995; 172:993-1000.
87. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann Intern Med 2001; 135:484-492. (Pubitemid 32923565)
88. Kuehnert MJ, Jernigan JA, Pullen AL, et al. Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients. Infect Control Hosp Epidemiol 1999; 20:660-663.
89. Timmers GJ, van der Zwet WC, Simoons-Smit IM, et al. Outbreak of vancomycin-resistant Enterococcus faecium in a haematology unit: risk factor assessment and successful control of the epidemic. Br J Haematol 2002; 116:826-833. (Pubitemid 34227002)
90. Matar MJ, Tarrand J, Raad I, Rolston KV. Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control 2006; 34:534-536. (Pubitemid 44479799)
91. Zaas AK, Song X, Tucker P, Perl TM. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 2002; 35:1139-1146. (Pubitemid 35305860)
92. Weinstock DM, Conlon M, Iovino C, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2007; 13:615-621. (Pubitemid 46585935)
93. Bossaer JB, Hall PD, Garrett-Mayer E. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer 2011; 19:231-237.
94. Bow EJ. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol 2009; 46:259-268.